Pharmaceuticals

ACE Inhibitors Market Growth Forecast With Analysis Of Industry Progress Through 2030

May 18, 2026May 18, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

What Market Size Is Forecasted For The ACE Inhibitors Market By 2030 Based On Its 2026 Value?

The ace inhibitors market has experienced significant growth in recent years. It will grow from $7.41 billion in 2025 to $7.84 billion in 2026 at a compound annual growth rate (CAGR) of 5.8%. This historical growth can be attributed to the increasing prevalence of hypertension, rising awareness about cardiovascular diseases, the introduction of first-generation ace inhibitors, a growing geriatric population, and advancements in drug formulation.

The market for ace inhibitors is projected to experience robust expansion over the coming years. This market is anticipated to reach $10.11 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 6.5%. Several factors will drive this growth during the forecast period, including the increasing demand for personalized medicine, the incorporation of digital health solutions, the enlargement of emerging markets, the creation of new ace inhibitor combinations, and the expansion of home healthcare services. Key trends expected during this period involve personalized approaches to hypertension management, the adoption of telemedicine and remote patient monitoring, the evolution of combination therapies, an increase in generic ace inhibitors, and the broadening of home healthcare options.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=10671&type=smp

What Important Drivers Are Powering The ACE Inhibitors Market Growth?

A projected rise in the occurrence of cardiac disorders is anticipated to drive the future growth of the ACE inhibitors market. Cardiac disorders are a category of medical conditions affecting the heart or blood vessels, covering a broad spectrum such as coronary artery disease, heart failure, and arrhythmias. ACE inhibitors are essential in managing these conditions, operating by inhibiting the angiotensin-converting enzyme, which helps to decrease vasoconstriction, sodium retention, and aldosterone secretion, ultimately improving heart function. For example, the American Heart Association, a US-based non-profit, reported in January 2024 that the age-adjusted death rate from cardiovascular disease rose to 233.3 per 100,000 in 2024, marking a 4.0% increase from 224.4 per 100,000 in 2023. This demonstrates how the increasing incidence of cardiac disorders is indeed fueling the expansion of the ACE inhibitors market.

What Key Segment Areas Are Included In The ACE Inhibitors Market Assessment?

The ace inhibitors market covered in this report is segmented –

1) By Type: Sulfhydryl-containing Agents, Dicarboxylate-containing Agents, Phosphonate-containing Agents

2) By Drug: Ramipril, Enalapril, Benazepril, Fosinopril, Captopril, Moexipril, Other Drugs

3) By Dosage Form: Oral Tablets, Oral Solutions

4) By Application: Heart Failure, Chronic Kidney Disease, Hypertension, Diabetes, Heart Attack, Other Applications

5) By End-Users: Hospitals, Online Drug Stores, Other End-Users

Subsegments:

1) By Sulfhydryl-Containing Agents: Captopril, Zofenopril

2) By Dicarboxylate-Containing Agents: Enalapril, Lisinopril, Ramipril, Quinapril, Benazepril, Perindopril

3) By Phosphonate-Containing Agents: Fosinopril, Fosinopril Sodium, Fosinopril Calcium

Which Trends Are Shaping The ACE Inhibitors Market Landscape?

Companies operating in the ACE inhibitor market are increasingly concentrating on introducing generic medications to secure a competitive advantage. A generic drug is a medicine that mirrors a brand-name drug in its active ingredients, dosage, safety profile, strength, administration route, and overall effectiveness, typically becoming available at a reduced cost once its original patent expires. For example, in August 2023, Pharmascience Inc., a pharmaceutical company based in Canada, launched pms-PERINDOPRIL-INDAPAMIDE. This generic medication is specifically formulated for the initial management of mild to moderate essential hypertension (high blood pressure) in adults. The combination product contains two active components: perindopril erbumine, an angiotensin-converting enzyme (ACE) inhibitor which helps relax blood vessels, and indapamide, a chlorosulphamoyl diuretic that facilitates the body’s removal of excess fluid and sodium. These ingredients work synergistically to effectively decrease blood pressure in a wide array of patients. pms-PERINDOPRIL-INDAPAMIDE is provided in various dosage forms, featuring 2 mg, 4 mg, and 8 mg of perindopril erbumine, each combined with 0.625 mg, 1.25 mg, and 2.5 mg of indapamide, respectively.

Which Firms Are Competing In The ACE Inhibitors Market?

Major companies operating in the ace inhibitors market are Pfizer Inc., Novartis AG, Johnson & Johnson Private Limited, Merck KGaA, Sanofi S.A., Bayer AG, Teva Pharmaceutical Industries Ltd., Bristol-Myers Squibb Co., Takeda Pharmaceuticals Company, Daiichi Sankyo Company Ltd., Endo International plc, Sun Pharmaceutical Industries Ltd., Boehringer Ingelheim, Bausch Health Companies Inc., Dr. Reddy’s Laboratories, Abbott Laboratories, Eli Lilly and Company, Cipla Limited, GlaxoSmithKline plc, Cadila Healthcare Limited, AbbVie Inc., Sandoz Group AG, Accord Healthcare Ltd., AstraZeneca plc, Lupin Limited, Macleods Pharmaceuticals Limited, Zydus lifescience Ltd., Apotex Inc.

Access The Complete ACE Inhibitors Market Report:

https://www.thebusinessresearchcompany.com/report/ace-inhibitors-global-market-report

Which Regional Market Leads The ACE Inhibitors Market?

North America was the largest region in the ACE inhibitors market in 2025. Asia-Pacific is expected to be the fastest-growing region in the global ACE inhibitors market report during the forecast period. The regions covered in the ace inhibitors market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access ACE Inhibitors Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/sample.aspx?id=10671&type=smp

Browse Through More Reports Similar to the Global ACE Inhibitors Market 2026, By The Business Research Company

Ace Inhibitors Market Report 2026

https://www.thebusinessresearchcompany.com/report/ace-inhibitors-global-market-report

Enzyme Inhibitor Market Report 2026

https://www.thebusinessresearchcompany.com/report/enzyme-inhibitor-global-market-report

Kinase Inhibitors Market Report 2026

https://www.thebusinessresearchcompany.com/report/kinase-inhibitors-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795